MX2022010902A - Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. - Google Patents

Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.

Info

Publication number
MX2022010902A
MX2022010902A MX2022010902A MX2022010902A MX2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A
Authority
MX
Mexico
Prior art keywords
lateral sclerosis
amyotrophic lateral
treating amyotrophic
myeloperoxidase inhibitor
myeloperoxidase
Prior art date
Application number
MX2022010902A
Other languages
English (en)
Inventor
Irfan Qureshi
Marianne Frost
Mary K Donohue
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2022010902A publication Critical patent/MX2022010902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un método para tratar la esclerosis lateral amiotrófica, que incluye administrar a un sujeto que necesite tal tratamiento una cantidad eficaz de un inhibidor de la mieloperoxidasa o una sal aceptable desde el punto de vista farmacéutico de esta.
MX2022010902A 2020-03-05 2021-03-05 Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. MX2022010902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985802P 2020-03-05 2020-03-05
PCT/US2021/020979 WO2021178734A1 (en) 2020-03-05 2021-03-05 Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor

Publications (1)

Publication Number Publication Date
MX2022010902A true MX2022010902A (es) 2022-10-07

Family

ID=77613802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010902A MX2022010902A (es) 2020-03-05 2021-03-05 Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.

Country Status (11)

Country Link
US (1) US20230130225A1 (es)
EP (1) EP4114370A4 (es)
JP (1) JP2023519662A (es)
KR (1) KR20220149709A (es)
CN (1) CN115916164A (es)
AU (1) AU2021230370A1 (es)
BR (1) BR112022017501A2 (es)
CA (1) CA3173805A1 (es)
IL (1) IL296151A (es)
MX (1) MX2022010902A (es)
WO (1) WO2021178734A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090053176A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US20210308077A1 (en) * 2017-04-20 2021-10-07 The Brigham And Women`S Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson`s disease and movement disorders
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors

Also Published As

Publication number Publication date
BR112022017501A2 (pt) 2022-10-18
AU2021230370A1 (en) 2022-10-20
CN115916164A (zh) 2023-04-04
EP4114370A4 (en) 2024-03-20
IL296151A (en) 2022-11-01
JP2023519662A (ja) 2023-05-12
WO2021178734A1 (en) 2021-09-10
KR20220149709A (ko) 2022-11-08
EP4114370A1 (en) 2023-01-11
US20230130225A1 (en) 2023-04-27
CA3173805A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
MX2023003583A (es) Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
MX2022010902A (es) Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
PH12022553441A1 (en) Compositions and methods for treating obsessive-compulsive disorder
MX2023009620A (es) Metodos terapeuticos.
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.
UY39593A (es) Tratamiento para tumores sólidos malignos